BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
- World
- Reuters
- Published Date: 03:25 | 29 June 2022
- Modified Date: 03:25 | 29 June 2022
Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.
Their experimental work on shots that go beyond the current approach include T-cell enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.
The two partners, makers of the Western world's most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages.
- UN mission to Mali extended, but without French air support
- US says Venezuela visit focused on Americans' welfare
- France, Türkiye committed to NATO’s unity, strength: French president
- Ukraine cuts ties with Syria after it recognises separatist republics
- Ultimate goal to 'liberate Donbas', NATO expansion 'no problem' for Russia: Putin